期刊文献+

5-氟尿嘧啶缓释剂在胰腺癌根治性切除术中植入疗效的研究 被引量:4

An analysis of intraperitoneal interstitial implant with sustained-release 5-fluorouracill during radical pancreatectomy for pancreatic cancer
下载PDF
导出
摘要 目的评价胰腺癌根治术中腹腔内植入5-氟尿嘧啶缓释剂的疗效。方法收集2008年1月~2011年1月106例行根治性切除术的胰腺癌患者的临床病理学资料,分析其临床病理学特征并分组,49例术中植入5-氟尿嘧啶缓释剂作为治疗组,57例未进行术中化疗作为对照组。观察两组临床受益反应及生存情况。结果治疗组与对照组临床受益率分别为65.3%和45.6%(P<0.05);中位生存时间分别为20和13个月(P<0.05);1年无病生存率分别为65.4%和39.1%(P<0.01);1年总生存率分别为71.3%和55.9%(P<0.05)。结论术中即时植入5-氟尿嘧啶缓释剂可降低胰腺癌患者术后肿瘤的复发,提高患者生活质量,明显延长生存时间。 Objective To assess the effect of interstitial implant with sustained-release 5-fluorouracill during radical pancreatectomy in pancreatic cancer.Methods The clinicopathological data were collected from 106 patients who had received surgical operation from January 2008 to January 2011.The clinicopathological features were retrospectively analyzed and were divided into 2 groups: treatment group(n=49),patients with intraoperative implant sustained-release 5-fluorouracill;control group(n=57),patients without intraperitoneal chemotherapy.The clinical benefit response(CBR) and survival of patients of the two groups were observed.Results In treatment group CBR rate was 65.3% and 45.6% for the control group(P〈0.05).Median survival time was 20 vs 13 months for the treatment and control group respectively(P〈0.05).Disease-free survival(DFS) rate was 65.4% of 1 year in treatment group,and in control group DFS rate was 39.1% of 1 year(P〈0.01).Overall survival(OS) rate was 71.3% of 1 year in treatment group,and in control group OS rate was 55.9% of 1 year(P〈0.05).Conclusion Intraperitoneal interstitial implant with sustained-release 5-fluorouracill is an effective measure to prevent local recurrence,improve the quality of life and prolong the survival rate in resected pancreatic cancer.
出处 《山东医药》 CAS 2012年第20期1-3,共3页 Shandong Medical Journal
基金 国家自然科学基金资助项目(30973490)
关键词 胰腺肿瘤 腹腔化疗 5-氟尿嘧啶缓释剂 生存分析 pancreatic neoplasms intraperitoneal chemotherapy sustained-release 5-fluorouracil survival analysis
  • 相关文献

参考文献7

二级参考文献71

共引文献144

同被引文献44

  • 1宋秀远.化疗药物常见副作用的护理[J].实用医技杂志,2006,13(1):150-151. 被引量:4
  • 2易峰涛,宋华志,李静.术中氩氦刀治疗晚期胰腺癌[J].中华肝胆外科杂志,2006,12(3):186-187. 被引量:13
  • 3胡凯文,李泉旺,左明焕,孙韬,姜敏.Clinical Observation on the Combined Treatment of 57 Cases of Non-small Cell Lung Cancer Using Argon-Helium Cryosurgery and Chinese Herbal Medicine[J].Chinese Journal of Integrative Medicine,2007,13(3):224-227. 被引量:7
  • 4Eisenhauer EA,Therasse P,Bogaerts J,et al.New response evaluation criteria in solid turnouts; revised RECIST guideline (version 1.1)[J].Eur J Cancer, 2009,45(2): 228-247.
  • 5Wojcicki M,Lubikowski J,Post M,et al.Aggressive surgfcal management of recurrent lymph node and pancreatic head metastases of resected fibrolamellar hepatocellular carcinoma: a case report[J].JOP,2012,13(5):529- 532.
  • 6Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Can- cer J Clin, 2011, 61(2): 69-90.
  • 7Hasegawa K, Kokudo N. Surgical treatment of hepatocellular carci- noma. Surg Today, 2009, 39(10): 833-843.
  • 8Sethna KS, Sugarbaker PH. New prospects for the control of peri- toneal surface dissemination of gastric cancer using perioperative intraperitoneal chemotherapy. Cancer Therapy, 2004, 2: 79-84.
  • 9中国抗癌协会肝癌专业委员会.原发性肝癌的临床诊断与分期标潍肝肺2004.(S1):67-68.
  • 10Cochrane handbook for systematic reviews of interventions (Version 5.0.2 updated September 2009). Available from: www.cochrane- handbook.org.

引证文献4

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部